Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib + gemcitabine in relapsed/refractory peripheral T-cell or NK/T-cell lymphomas
KCT0003053Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2018
- Countries
- 1
- Sponsor
- Bayer
- Modality
- Small Molecules
- Conditions
- peripheral T cell lymphomas (PTCL)natural killer-cell lymphoma (NK/TCL)
01
Overview
Phase 2, open-label, single-arm trial of copanlisib and gemcitabine in peripheral T cell lymphomas (PTCL) and natural killer-cell lymphoma (NK/TCL), sponsored by Bayer. Started Mar 2018; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Copanlisib + gemcitabine
Single treatment arm receiving copanlisib (BAY 80-6946) in combination with gemcitabine for relapsed/refractory peripheral T-cell or NK/T-cell lymphomas.
03
Who it enrols
Adult patients with histologically confirmed relapsed or refractory peripheral T-cell or NK/T-cell lymphomas after at least one prior systemic therapy, with adequate performance status and organ function, and without uncontrolled infection or pregnancy.
Beyond the preview
Go deeper on KCT0003053.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003053.